Trunome Heart Care test uses advanced technology to determine the risk of transplant rejection through a straightforward blood sample. Early identification of rejection can help avoid the loss of a transplanted heart and aid in the development of a treatment plan to protect the transplanted organ.
The Trunome Heart Care test provides a non-invasive way to evaluate the risk of transplant rejection by analyzing a simple blood sample. Early detection of transplant rejection is crucial because it can prevent transplant failure, enhance patient outcomes, and eliminate the need for additional transplants.
Without effective testing and treatment, many transplanted organs, particularly hearts, can fail shortly after the transplantation. Early detection and intervention can improve patient life and reduce the need to go through the lengthy waitlist process again.
Why use a blood test to monitor a transplanted heart?
The Trunome Heart Care test offers a vital tool in ensuring the long-term success of heart transplants by providing regular, non-invasive monitoring through blood tests. The blood test helps to detects the presence of antibodies or other markers indicating rejection or injury, allowing healthcare providers to take early action to protect the transplanted heart and improve patient outcomes.
The benefits of Trunome’s test, such as its ease of use and the ability to provide repeated sampling for longitudinal analysis, make it essential in safeguarding the patient’s health and enhancing the overall quality of their life after transplantation.
Trunome is a non-invasive method, with a simple blood draw from the post-transplant patient. The collected blood is then analyzed to measure the amount of donor DNA from the transplanted kidney in the patient’s blood.
This measurement can help assess all types of organ rejection more precisely than standard assessment tools that are currently available.